Full Text (PDF)
Mycoplasma is known to be a common source of bioprocessing contamination and one of the most difficult contaminants to detect. The effect of a mycoplasma contamination can be catastrophic, resulting in loss of a batch, loss of future production, down-time for investigation and corrective actions, and the potential risk of therapeutic supply shortages to immunocompromised patients.
To demonstrate Millipore Express SHR filters' mycoplasma clearance capability over extended filtration times, two separate Acholeplasma laidlawii retention studies were performed using sterilizing-grade Millipore Express SHR with Prefilter (0.1-µm polyethersulfone) filters and A. laidlawii ATCC® 23206. In these experiments, the test conditions were modeled after typical cell culture processes, and testing was conducted using a low organism challenge level and typical operating pressures. The first experiment tested filters at production scale in a 3×30″ cartridge configuration (44,100 cm2). A second experiment tested the retention of A. laidlawii using Opticap® XL300 pilot-scale capsules.
BackgroundCurrently, no standard industry method exists for testing filters for mycoplasma retention; however, Millipore has a validated procedure for mycoplasma testing that is modeled after the current ASTM® F838-05 test for sterilizing-grade filters. Similar to the ASTM test protocol, this involves using a high challenge level of A. laidlawii (≥107 colony-forming units per cm2 of effective filtration area) and a high differential pressure (30 psid). These severe testing parameters simulate worst-case testing parameters and provide a high degree of assurance that a filter that passes this test will quantitatively retain large numbers of organisms.
Whereas this testing regime is useful in providing a quantitative assessment of sterilizing-grade filter performance, these conditions are not typical of a pharmaceutical biomanufacturing process. As a result, the following two additional experiments were performed to examine filter performance at pilot and production scale under test conditions that more closely model typical cell culture filtration operating parameters.
ProcedureProduction Scale Testing 3×30″ Configuration: The 3×30″ filter extended challenge test was scaled from an established filtration process using 47-mm membrane disc filters (13.8 cm2 of total effective filtration area). For this test, three 30-in. Millipore Express SHR with prefilter cartridges (44,100 cm2 of total effective filtration area) were challenged over five hours at a flow rate of 667 mL/min. (Flux 9.1 LMH). Following the filter challenge, A. laidlawii culturing, recovery, and enumeration were performed.
Pilot Scale Testing: Opticap XL 300 Configuration: The Opticap XL300 (290 cm2 effective filtration area) pilot scale capsule (SSC) extended challenge test was adapted from an established process with a few modifications for test stand setup, challenge, and flush volumes. A. laidlawii culturing, recovery, and enumeration were performed. For the duration of the test, pressure was driven at 10 psid with a flow of 300 mL/minute (Flux 620.7 LMH) for an extended challenge time of eight hours.
ResultsFor all experiments, the system sterility met the acceptance criteria demonstrating the absence of microbial growth and indicating that all equipment was properly sterilized. The average delivered challenge level was 4.85×104 CFU/cm2 for the 3×30″ configuration and 7.81×105 CFU/cm2 for the Opticap XL300 capsules. There was zero passage of challenge organism detected downstream of the 3×30″ cartridge filters (LRV ≥ 4.0). The limit of detection for the 3×30″ configuration experiment was 40 CFU. There was zero passage of challenge organism detected downstream of the Opticap XL 300 capsules (LRV ≥ 8.35). The LOD for the Opticap XL300 capsule experiments was 1 CFU.
ConclusionChallenge testing performed at pilot and production scales using A. laidlawii demonstrated that Millipore Express SHR with prefilter cartridge filters in a 3×30″ configuration were fully retentive when challenged with 200 L of A. laidlawii at a concentration of 1×104 CFU/cm2 over five hours. The Opticap XL300 pilot-scale capsules were also fully retentive when challenged at an average A. laidlawii level of 7.81×105 CFU/cm2 over eight hours. These tests demonstrate Millipore Express SHR filters' mycoplasma retention capability at typical cell culture filtration operating parameters and extended processing times.
Christine Wright is a microbiological scientist, Laurelle Sciola is a product manager, and Danielle Decesaro is an R&D technician at Millipore Corporation, 290 Concord Road, Billerica, MA 01821; 1-800-645-5476.
Facility Design Strategies for Single-Use Technologies
Please join us for a free webinar addressing strategies for facility design in biopharmaceutical manufacturing:
Wednesday, 29 February 2012
8:00 AM and 1:00 PM EST
Presented by:
Ingrid Long, MSc
Research Engineer
GE Healthcare Life Sciences
During the webinar, Ms. Long will discuss the impact of different strategies for facility design, with a focus on the following topics:
* Replacement of traditional equipment with the single-use equivalent
* Biopharmaceutical manufacturing in a single room
* Benefits of facility design with respect to cost, risk, and flexibility



